Clinical Trial Update: Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet [Phase 4]

View source ↗

Summary

A Phase 4 bioequivalence study evaluating a new 80 mg atorvastatin tablet versus a commercial 80 mg atorvastatin tablet has been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• atorvastatin (80 mg, commercial tablet) (atorvastatin)
• atorvastatin (80 mg, new formulation) (atorvastatin)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Hypercholesterolemia | Phase 4 | Status: COMPLETED | Results posted: 2009-10-15